FLQ-101 for ROP
(tROPhy-1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called FLQ-101, an experimental therapy for retinopathy of prematurity (ROP), which affects the eyes of premature babies. The main goal is to determine if FLQ-101 is safe and effective for these infants. Babies born between 26 and 28 weeks of pregnancy and weighing at least 650 grams might qualify. The trial excludes those with certain health issues, such as serious heart problems or eye conditions. As a Phase 1 trial, this research aims to understand how FLQ-101 works in people, offering participants the opportunity to be among the first to receive this new treatment.
Is there any evidence suggesting that FLQ-101 is likely to be safe for humans?
Research shows that FLQ-101 is undergoing safety testing in premature babies with retinopathy of prematurity (ROP). As a phase 1 study, this likely marks one of the first human trials of FLQ-101, so detailed safety information may not yet be available. However, the FDA has granted the drug fast track status, indicating potential significant benefits and an urgent need for this treatment. Fast track status often suggests promise in early tests. Nonetheless, further research is necessary to determine how well FLQ-101 is tolerated and to identify any potential side effects.12345
Why do researchers think this study treatment might be promising?
FLQ-101 is unique because it introduces a new approach to treating Retinopathy of Prematurity (ROP). Unlike current treatments like laser therapy and anti-VEGF injections, which primarily focus on halting abnormal blood vessel growth, FLQ-101 targets the underlying molecular pathways involved in ROP. Researchers are excited about this treatment because it has the potential to be more precise in its action, possibly reducing the risk of side effects and improving outcomes for premature infants with ROP.
What evidence suggests that FLQ-101 might be an effective treatment for ROP?
Research has shown that FLQ-101 is designed to help with retinopathy of prematurity (ROP), a condition affecting the eyes of premature babies that can lead to blindness. This treatment aims to improve blood vessel growth in the eye and reduce swelling. The FDA granted FLQ-101 fast track status, indicating its promise in preventing ROP and recognizing its potential benefits. Although limited data exist from human studies, the treatment's approach appears promising for aiding premature infants with ROP.12346
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive FLQ-101 to evaluate safety and efficacy outcomes
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- FLQ-101
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
FELIQS INC.
Lead Sponsor
Citations
FELIQS ROP Treatment
Japanese drugmaker reports plans to conduct a phase1b/2 study of FLQ-101, a preventative treatment for retinopathy of prematurity, in early 2025.
Safety, PK and PD of FLQ-101 in Premature Neonates
Study Overview. Brief Summary. The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.
FELIQS secures $9m for FLQ-101 to prevent ROP
FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for ROP.
Current evidence and outcomes for retinopathy of prematurity ...
Retinopathy of prematurity (ROP) represents a significant clinical problem accounting for up to 40% of childhood blindness worldwide with an estimated incidence ...
Retinopathy of Prematurity Market Report, Market trends
Retinopathy of Prematurity Market Size was valued ~13 million in 2023 whihc is expected to grow during study period from 2020-2034.
6.
trial.medpath.com
trial.medpath.com/clinical-trial/f00ac270d3a635e0/nct07093255-flq-101-safety-pharmacokinetics-pharmacodynamics-premature-neonates-ropSafety, PK and PD of FLQ-101 in Premature Neonates
The purpose of this study is to evaluate safety and efficacy outcomes following exposure to FLQ-101.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.